SOX as Adjuvant Chemotherapy for Resectable Gastric Cancer

Phase 1/2 Unknown 71 enrolled Chinese Academy of Medical Sciences

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and efficacy of S-1 plus oxaliplatin combination chemotherapy based on the adverse events and survival period by performing a phase I/II study of this combination in patients with D2 resection of gastric cancer.

Timeline

Start: 2011-06
Primary completion: 2014-09
Completion: 2017-04

Publications

Wang G, Zhao J, Song Y, Zhang W, Sun Y, Zhou A, Huang J, Du F, Yang L. Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer. BMC Cancer. 2018 May 9;18(1):547. doi: 10.1186/s12885-018-4480-9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Oxaliplatin	Small molecule	130 mg/m2	Intravenous
Subject	S-1	Small molecule	60 mg/m2	Oral
Subject	S-1	Small molecule	90 mg/m2	Oral

SOX as Adjuvant Chemotherapy for Resectable Gastric Cancer

Summary

Timeline

Publications

Drugs

Indications